ClinicalTrials.gg
CompletedNCT05321069Updated Oct 20, 2025Results posted

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 interventional study of BI 1015550 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 334 sites in 37 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,177
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
2nd of 18
1,177 · median 109
Started
2022
the only one that year
Phase 3
5 of 36
none open now
Registered
25th of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 3, and was the 25th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older. If they already take nintedanib or pirfenidone for their IPF, they can continue treatment throughout the study. The purpose of this study is to find out whether a medicine called BI 1015550 helps people with IPF.

Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of BI 1015550 as tablets twice a day. Participants in the placebo group take placebo tablets twice a day. Placebo tablets look like BI 1015550 tablets but do not contain any medicine.

Participants are in the study for up to two and a half years. During the first year, they visit the study site 10 times. Afterwards, they visit the study site every 3 months. The doctors regularly test participants' lung function. The results of the lung function tests are compared between the groups. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥40 years old at the time of signed .
  2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF).
  4. Patients may be either:

    • on a stable therapy* with nintedanib or pirfenidone for at least 12 weeks prior to Visit 1 and during screening and are planning to stay on this background treatment after randomization. Combination of nintedanib plus pirfenidone is not allowed. (*stable therapy is defined as the individually and general tolerated regimen of either nintedanib or pirfenidone (no dose changes) for at least 12 weeks).
    • not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to Visit 1 and during the screening period (e.g. either Antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start antifibrotic treatment.
  5. Forced Vital Capacity (FVC) ≥45% of predicted normal at Visit 1.
  6. Diffusing Capacity (of Lung) for Carbon Monoxide (DLCO) ≥25% of predicted normal corrected for (Hb) at Visit 1.
  7. Women of (WOCBP) must be ready and able to use highly effective methods of . WOCBP taking oral contraceptives (OCs) also have to use one barrier method.

Exclusion criteria

Exclusion criteria

  1. Prebronchodilator (FEV1)/Forced vital capacity (FVC) \<0.7 at Visit 1.
  2. In the opinion of the Investigator, other pulmonary abnormalities.
  3. Acute Idiopathic Pulmonary Fibrosis (IPF) exacerbation within 3 months prior to Visit 1 and/or during the screening period (investigator-determined).
  4. Relevant chronic or acute infections including (HIV) and viral hepatitis.
  5. Confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) not fully recovered according to investigator judgement within the 4 weeks prior to randomization (Visit 2).
  6. Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to Visit 2 or planned during the trial period, e.g. hip replacement. Registration on lung transplantation list would not be considered as planned major surgery.
  7. Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  8. (AST) or Alanine Aminotransferase (ALT) >2.5 x (ULN) or total >1.5 x ULN at Visit 1.

Further exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,177 participants (actual)

Study arms

  • Experimental
    Nerandomilast 9 mg BID

    Participants received 9 mg film-coated nerandomilast tablets orally twice daily, with doses administered at least 12 hours apart, each taken with 250 mL of water.

    Drug: BI 1015550

  • Experimental
    Nerandomilast 18 mg BID

    Participants received 18 mg film-coated nerandomilast tablets orally twice daily, with doses administered at least 12 hours apart, each taken with 250 mL of water.

    Drug: BI 1015550

  • Placebo comparator
    Placebo

    Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally twice daily, with doses given at least 12 hours apart and each taken with 250 mL of water.

    Drug: Placebo

Interventions

  • Participants received film-coated nerandomilast tablets orally twice daily at doses of either 9 mg or 18 mg, with each dose administered at least 12 hours apart and taken with 250 mL of water.

    Also known as: Nerandomilast, JASCAYD®

  • DrugPlacebo

    Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally twice daily, with doses given at least 12 hours apart and each taken with 250 mL of water.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52

    The absolute change from baseline in Forced Vital Capacity (FVC) \[mL\] at Week 52 is reported. The absolute change from baseline in forced vital capacity (FVC) at Week 52 was analyzed using a restricted maximum likelihood (REML)-based mixed model with repeated measures (MMRM). The model included fixed categorical effects of treatment and baseline antifibrotic use at each visit, as well as the continuous effect of baseline FVC. Visit was treated as a repeated measure, with an unstructured covariance structure for within-patient variability.

    Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52

Secondary outcomes

  1. Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial

    Time to the first occurrence of any component of the composite endpoint-acute IPF exacerbation, hospitalization for a respiratory cause, or death (whichever occurred first)-is reported as the number of participants who experienced one or more of these events during the trial. Acute IPF is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, with all of the following: Acute worsening or development of dyspnea, typically of less than 1 month's duration. Computed tomography showing new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with IPF. Deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation, hospitalization, death.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  2. Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial

    The time to first acute IPF exacerbation or death during the trial is reported as the number of participants who experienced either event. Acute IPF is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, with all of the following: Acute worsening or development of dyspnea, typically of less than 1 month's duration. Computed tomography showing new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with IPF. Deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation followed by death.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  3. Time to Hospitalization for Respiratory Cause or Death Over the Duration of the Trial

    Time to hospitalization for respiratory cause or death over the duration of the trial is reported as the number of participants who experienced either event. Hospitalizations due to respiratory causes were recorded on a specific non-elective hospitalization CRF page. This page captured the hospitalization date, confirmation of a respiratory cause, and the primary admission diagnosis. If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: hospitalization for respiratory cause, followed by death.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  4. Time to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial

    The time to absolute decline of more than 10% from baseline in forced vital capacity (FVC) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy; Absolute decline in FVC % predicted of \> 10% followed by death.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  5. Time to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial

    The time to absolute decline of more than 15% from baseline in diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. Predicted DLCO value was corrected for hemoglobin (Hb). If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: Absolute decline in DLCO % predicted of \> 15%, followed by Death.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  6. Time to Death Over the Duration of the Trial

    Time to death over the duration of the trial is reported as the number of participants who died. Time to death will be based either on the date of death on the AE report for patients with AEs leading to death or will be based on the information from the vital status assessment.

    Time frame: From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.

  7. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52

    The absolute change from baseline in the Living with Pulmonary Fibrosis (L-PF) Symptoms Dyspnea domain score at Week 52 is reported. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline use of antifibrotic therapy, and baseline dyspnea score at each visit, with an unstructured covariance structure to model repeated measures. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.

  8. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52

    The absolute change from baseline in the L-PF Cough domain score at Week 52 is reported. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, and baseline L-PF Cough score at each visit, with an unstructured covariance matrix for repeated measures. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.

  9. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52

    The absolute change from baseline in the Living with Pulmonary Fibrosis (L-PF) Fatigue domain score at Week 52 is reported. The analysis used a mixed model for repeated measures (MMRM) with fixed categorical effects for treatment, baseline antifibrotic (AF) therapy, and the fixed continuous effect of baseline L-PF score. Covariance was unstructured. Baseline AF therapy was a covariate. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.

  10. Absolute Change From Baseline in Forced Vital Capacity Percent Predicted at Week 52

    The absolute change from baseline in Forced Vital Capacity percent predicted at Week 52 is reported. Analysis was based on a Mixed Model for Repeated Measures (MMRM), which included fixed, categorical effects of treatment at each visit, baseline use of antifibrotic therapy at each visit, and the fixed continuous effects of baseline forced vital capacity (FVC) percentage predicted at each visit. An unstructured covariance structure was used to model repeated measures within patients. Baseline use of antifibrotic therapy, as recorded in the concomitant medication case report form (CRF) page, was included as a covariate.

    Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.

  11. Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide Percent Predicted at Week 52

    The absolute change from baseline in Diffusing Capacity of the Lungs for Carbon Monoxide percent predicted at Week 52 is reported. The analysis was based on a Mixed Model for Repeated Measures (MMRM), which included fixed, categorical effects of treatment at each visit, baseline use of antifibrotic therapy at each visit, and the fixed continuous effects of baseline diffusing capacity of the lungs for carbon monoxide (DLCO) percentage predicted at each visit. An unstructured covariance structure was used to model repeated measures within patients. Baseline use of antifibrotic therapy, as recorded in the concomitant medication case report form (CRF) page, was included as a covariate.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated DLCO measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, and Week 52. The data represent the Least Squares Mean at Week 52.

07

Results

Posted Sep 12, 2025

Participant flow

This was a randomized, double-blind, placebo-controlled, multi-centre, Phase III trial evaluating the efficacy, safety, and tolerability of nerandomilast (BI 1015550) 9 mg and 18 mg bid versus placebo in patients with IPF. The trial included two parts: Treatment Period A lasted up to 52 weeks post-randomisation, followed by Treatment Period B with continued blinded treatment for a variable duration beyond 52 weeks.

Participant flow — Overall Study
MilestonePlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Started393392392
Completed treatment period a (52 weeks)320324318
Completed292298299
Not completed1019493
Withdrew: Adverse event525264
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject231812
Withdrew: Lost to follow-up101
Withdrew: No reason stated by the participants232216
Withdrew: Lack of efficacy110

Outcome measures

PrimaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52

The absolute change from baseline in Forced Vital Capacity (FVC) \[mL\] at Week 52 is reported. The absolute change from baseline in forced vital capacity (FVC) at Week 52 was analyzed using a restricted maximum likelihood (REML)-based mixed model with repeated measures (MMRM). The model included fixed categorical effects of treatment and baseline antifibrotic use at each visit, as well as the continuous effect of baseline FVC. Visit was treated as a repeated measure, with an unstructured covariance structure for within-patient variability.

Time frame:
The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52
Reported as:
Least squares mean · Milliliters (mL)
Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52
Milliliters (mL)PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52-183.48 (-210.86 to -156.10)-138.60 (-165.59 to -111.61)-114.65 (-141.81 to -87.50)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.0222 · Mean difference (net): 44.89 · 95% CI 6.44 to 83.33Adjusted mean difference in FVC change from baseline at Week 52 between the Nera 9 mg bid group and the Placebo group.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.0005 · Mean difference (net): 68.83 · 95% CI 30.26 to 107.39Adjusted mean difference in FVC change from baseline at Week 52 between the Nera 18 mg bid group and the Placebo group.
SecondaryKey Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial

Time to the first occurrence of any component of the composite endpoint-acute IPF exacerbation, hospitalization for a respiratory cause, or death (whichever occurred first)-is reported as the number of participants who experienced one or more of these events during the trial. Acute IPF is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, with all of the following: Acute worsening or development of dyspnea, typically of less than 1 month's duration. Computed tomography showing new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with IPF. Deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation, hospitalization, death.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Key Secondary Endpoint: Time to the First Occurrence of Any of the Components of the Composite Endpoint: Time to First Acute IPF Exacerbation, First Hospitalization for Respiratory Cause, or Death (Whichever Occurs First) Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Acute IPF exacerbation as the first event383238
Hospitalisation for respiratory cause as the first event494547
Death as the first event16138
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.5443 · Hazard ratio (hr): 0.92 · 95% CI 0.69 to 1.22
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.9512 · Hazard ratio (hr): 0.99 · 95% CI 0.75 to 1.31
SecondaryTime to First Acute IPF Exacerbation or Death Over the Duration of the Trial

The time to first acute IPF exacerbation or death during the trial is reported as the number of participants who experienced either event. Acute IPF is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, with all of the following: Acute worsening or development of dyspnea, typically of less than 1 month's duration. Computed tomography showing new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with IPF. Deterioration not fully explained by cardiac failure or fluid overload. If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation followed by death.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Time to First Acute IPF Exacerbation or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Acute IPF exacerbation303138
Death192012
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.5583 · Hazard ratio (hr): 1.12 · 95% CI 0.76 to 1.67
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.5896 · Hazard ratio (hr): 1.11 · 95% CI 0.75 to 1.65
SecondaryTime to Hospitalization for Respiratory Cause or Death Over the Duration of the Trial

Time to hospitalization for respiratory cause or death over the duration of the trial is reported as the number of participants who experienced either event. Hospitalizations due to respiratory causes were recorded on a specific non-elective hospitalization CRF page. This page captured the hospitalization date, confirmation of a respiratory cause, and the primary admission diagnosis. If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: hospitalization for respiratory cause, followed by death.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Time to Hospitalization for Respiratory Cause or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Hospitalization for respiratory cause595768
Death14117
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.9038 · Hazard ratio (hr): 0.98 · 95% CI 0.70 to 1.36
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.4687 · Hazard ratio (hr): 1.13 · 95% CI 0.82 to 1.56
SecondaryTime to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial

The time to absolute decline of more than 10% from baseline in forced vital capacity (FVC) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy; Absolute decline in FVC % predicted of \> 10% followed by death.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Time to Absolute Decline in Forced Vital Capacity (FVC) % Predicted of >10% From Baseline or Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute decline in FVC % predicted of > 10%918980
Death201814
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.7695 · Hazard ratio (hr): 0.96 · 95% CI 0.74 to 1.25
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.2068 · Hazard ratio (hr): 0.84 · 95% CI 0.64 to 1.10
SecondaryTime to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial

The time to absolute decline of more than 15% from baseline in diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event. Predicted DLCO value was corrected for hemoglobin (Hb). If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: Absolute decline in DLCO % predicted of \> 15%, followed by Death.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Time to Absolute Decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Percentage Predicted by More Than 15% From Baseline or Death, Measured Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute decline in DLCO % predicted of > 15%383543
Death282416
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.9251 · Hazard ratio (hr): 0.98 · 95% CI 0.69 to 1.41
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.4988 · Hazard ratio (hr): 0.88 · 95% CI 0.62 to 1.26
SecondaryTime to Death Over the Duration of the Trial

Time to death over the duration of the trial is reported as the number of participants who died. Time to death will be based either on the date of death on the AE report for patients with AEs leading to death or will be based on the information from the vital status assessment.

Time frame:
From first administration of any trial drug (Nerandomilast or Placebo) up to 22.9 months.
Reported as:
Count of participants · Participants
Time to Death Over the Duration of the Trial
ParticipantsPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Time to Death Over the Duration of the Trial282621
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Regression, Cox · p = 0.9084 · Hazard ratio (hr): 1.03 · 95% CI 0.60 to 1.76
  • Placebo vs Nerandomilast 18 mg BID · Regression, Cox · p = 0.4682 · Hazard ratio (hr): 0.81 · 95% CI 0.46 to 1.43
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52

The absolute change from baseline in the Living with Pulmonary Fibrosis (L-PF) Symptoms Dyspnea domain score at Week 52 is reported. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline use of antifibrotic therapy, and baseline dyspnea score at each visit, with an unstructured covariance structure to model repeated measures. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 527.26 (5.70 to 8.82)6.26 (4.71 to 7.80)6.63 (5.09 to 8.17)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.3697 · Mean difference (net): -1.00 · 95% CI -3.20 to 1.19The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Dyspnea score) between the Nera 9mg BID group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.5734 · Mean difference (net): -0.63 · 95% CI -2.83 to 1.57The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Dyspnea score) between the Nera 18mg BID group and the Placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52

The absolute change from baseline in the L-PF Cough domain score at Week 52 is reported. This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, and baseline L-PF Cough score at each visit, with an unstructured covariance matrix for repeated measures. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 524.54 (2.49 to 6.59)4.44 (2.42 to 6.46)3.95 (1.93 to 5.97)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.9442 · Mean difference (net): -0.10 · 95% CI -2.98 to 2.77The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Cough score) between the Nera 9 mg BID group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.6862 · Mean difference (net): -0.59 · 95% CI -3.47 to 2.28The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Cough score) between the Nera 18 mg BID group and the Placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52

The absolute change from baseline in the Living with Pulmonary Fibrosis (L-PF) Fatigue domain score at Week 52 is reported. The analysis used a mixed model for repeated measures (MMRM) with fixed categorical effects for treatment, baseline antifibrotic (AF) therapy, and the fixed continuous effect of baseline L-PF score. Covariance was unstructured. Baseline AF therapy was a covariate. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated L-PF measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.
Reported as:
Least squares mean · Score on a scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 52
Score on a scalePlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Fatigue Domain Score at Week 525.40 (3.66 to 7.14)5.59 (3.88 to 7.30)5.82 (4.11 to 7.54)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.8759 · Mean difference (net): 0.19 · 95% CI -2.25 to 2.63The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Fatigue score) between the Nera 9 mg BID group and the Placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.7320 · Mean difference (net): 0.43 · 95% CI -2.02 to 2.87The adjusted mean difference represents the model-estimated difference in symptom change (L-PF Fatigue score) between the Nera 18 mg BID group and the Placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Forced Vital Capacity Percent Predicted at Week 52

The absolute change from baseline in Forced Vital Capacity percent predicted at Week 52 is reported. Analysis was based on a Mixed Model for Repeated Measures (MMRM), which included fixed, categorical effects of treatment at each visit, baseline use of antifibrotic therapy at each visit, and the fixed continuous effects of baseline forced vital capacity (FVC) percentage predicted at each visit. An unstructured covariance structure was used to model repeated measures within patients. Baseline use of antifibrotic therapy, as recorded in the concomitant medication case report form (CRF) page, was included as a covariate.

Time frame:
The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52.
Reported as:
Least squares mean · FVC percent predicted
Absolute Change From Baseline in Forced Vital Capacity Percent Predicted at Week 52
FVC percent predictedPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Forced Vital Capacity Percent Predicted at Week 52-4.92 (-5.67 to -4.18)-3.75 (-4.48 to -3.01)-3.19 (-3.93 to -2.45)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.0280 · Mean difference (net): 1.17 · 95% CI 0.13 to 2.22The adjusted mean difference represents the model-estimated difference in percent predicted Forced Vital Capacity between the Nera 9 mg BID group and the placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.0013 · Mean difference (net): 1.73 · 95% CI 0.68 to 2.78The adjusted mean difference represents the model-estimated difference in percent predicted Forced Vital Capacity between the Nera 18 mg BID group and the placebo group at Week 52.
SecondaryAbsolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide Percent Predicted at Week 52

The absolute change from baseline in Diffusing Capacity of the Lungs for Carbon Monoxide percent predicted at Week 52 is reported. The analysis was based on a Mixed Model for Repeated Measures (MMRM), which included fixed, categorical effects of treatment at each visit, baseline use of antifibrotic therapy at each visit, and the fixed continuous effects of baseline diffusing capacity of the lungs for carbon monoxide (DLCO) percentage predicted at each visit. An unstructured covariance structure was used to model repeated measures within patients. Baseline use of antifibrotic therapy, as recorded in the concomitant medication case report form (CRF) page, was included as a covariate.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated DLCO measurements from baseline (Week -8 to Week -1) and Week 12, Week 26, and Week 52. The data represent the Least Squares Mean at Week 52.
Reported as:
Least squares mean · DLCO percent predicted
Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide Percent Predicted at Week 52
DLCO percent predictedPlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BID
Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide Percent Predicted at Week 52-6.14 (-7.35 to -4.94)-3.66 (-4.85 to -2.46)-4.47 (-5.66 to -3.27)
Statistical analysis
  • Placebo vs Nerandomilast 9 mg BID · Mixed Models Analysis · p = 0.0042 · Mean difference (net): 2.49 · 95% CI 0.79 to 4.19The adjusted mean difference represents the model-estimated difference in percent predicted DLCO between the Nera 9 mg BID group and the placebo group at Week 52.
  • Placebo vs Nerandomilast 18 mg BID · Mixed Models Analysis · p = 0.0530 · Mean difference (net): 1.67 · 95% CI -0.02 to 3.37The adjusted mean difference represents the model-estimated difference in percent predicted DLCO between the Nera 18 mg BID group and the placebo group at Week 52.

Adverse events

Collected over AE collection and All-cause mortality From first trial drug administration (Placebo or Nerandomilast) up to 22.9 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo42/393 (10.7%)181/393 (46.1%)316/393 (80.4%)
Nera 9 mg BID36/392 (9.2%)159/392 (40.6%)319/392 (81.4%)
Nera 18 mg BID26/392 (6.6%)165/392 (42.1%)337/392 (86%)
Most frequent serious events
Showing 10 of 359
Most frequent serious events
EventPlaceboNera 9 mg BIDNera 18 mg BID
Condition aggravatedGeneral disorders34/39328/39232/392
PneumoniaInfections and infestations22/39318/39217/392
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders12/39313/39211/392
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders12/3939/39212/392
Respiratory failureRespiratory, thoracic and mediastinal disorders9/3934/3924/392
PneumothoraxRespiratory, thoracic and mediastinal disorders2/3934/3928/392
DyspnoeaRespiratory, thoracic and mediastinal disorders7/3937/3926/392
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/3935/3925/392
Pneumonia bacterialInfections and infestations1/3936/3921/392
Cardiac failureCardiac disorders3/3931/3925/392
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboNera 9 mg BIDNera 18 mg BID
DiarrhoeaGastrointestinal disorders75/393130/392166/392
CoughRespiratory, thoracic and mediastinal disorders79/39374/39273/392
COVID-19Infections and infestations61/39374/39259/392
DyspnoeaRespiratory, thoracic and mediastinal disorders58/39350/39244/392
Upper respiratory tract infectionInfections and infestations47/39349/39256/392
Weight decreasedInvestigations39/39345/39254/392
NasopharyngitisInfections and infestations53/39346/39249/392
AnxietyPsychiatric disorders40/39335/39244/392
DepressionPsychiatric disorders38/39342/39242/392
Decreased appetiteMetabolism and nutrition disorders28/39339/39241/392

Baseline characteristics

Full Analysis Set (FAS): This patient set includes all randomized patients who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BIDTotal
Mean69.9 ± 7.570.5 ± 7.870.3 ± 7.870.2 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BIDTotal
Female567569200
Male337317323977
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BIDTotal
Hispanic or Latino28234495
Not Hispanic or Latino3653693481082
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BIDTotal
American Indian or Alaska Native1225
Asian116121130367
Native Hawaiian or Other Pacific Islander0000
Black or African American2316
White273266258797
More than one race1012
Unknown or Not Reported0000
Forced Vital Capacity (FVC) at baseline
Forced Vital Capacity (FVC) at baseline(Milliliters (mL))PlaceboNerandomilast 9 mg BIDNerandomilast 18 mg BIDTotal
Mean2863.9 ± 804.62837.2 ± 781.42827.3 ± 758.02842.8 ± 781.1
08

Study locations

334 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Christiana Hospital
    Newark, Delaware 19713, United States
  • Georgetown University
    Washington D.C., District of Columbia 20007, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida Health Shands Hospital
    Gainesville, Florida 32610, United States
  • Clinical Research Specialists LLC
    Kissimmee, Florida 34746, United States
  • Advanced Pulmonary Research Institute
    Loxahatchee Groves, Florida 33470, United States
  • Destin Pulmonary Critical Care
    Santa Rosa Beach, Florida 32459, United States
  • Piedmont Healthcare-Atlanta-57055
    Atlanta, Georgia 30309, United States
  • Evanston Hospital Pulmonary Clinic
    Evanston, Illinois 60201, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Louisville Pulmonary Care
    Louisville, Kentucky 40207, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • St. Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-5314, United States
  • Beaumont Health
    Royal Oak, Michigan 48073, United States
  • Minnesota Lung Center and Sleep Institute
    Edina, Minnesota 55435, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Creighton University
    Omaha, Nebraska 68124, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Renown Regional Medical Center
    Reno, Nevada 89502, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Northern Westchester Hospital
    Mount Kisco, New York 10549, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • Weill Cornell Medicine-New York-59955
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Southeastern Research Center-Winston-Salem-61365
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson Health Honickman Center
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Lowcountry Lung and Critical Care
    Charleston, South Carolina 29406, United States
  • Clinical Trials Center of Middle Tennessee, LLC
    Franklin, Tennessee 37067, United States
  • Vanderbilt University Medical Center - Vanderbilt Lung Institute at 100 Oaks
    Nashville, Tennessee 37204, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553
    C.a.b.a, 1056, Argentina
  • CEDIC - Centro de Investigacion Clinica
    CABA, C1060ABN, Argentina
  • Hospital Italiano de Buenos Aires
    CABA, C1199ABB, Argentina
  • Consultorios Médicos del Buen Ayre
    Capital Federal, C1425FVH, Argentina
  • Instituto Ave Pulmo
    Mar del Plata, 7600, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Centro Respiratorio de Quilmes
    Quilmes, B1878FNR, Argentina
  • Canberra Hospital
    Canberra, Australian Capital Territory 2605, Australia
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Lung Research Queensland
    Chermside, Queensland 4032, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Lung Research Victoria
    Footscray, Victoria 3011, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Trialswest
    Spearwood, Western Australia 6163, Australia
  • LKH Klagenfurt am Woerthersee
    Klagenfurt, 9020, Austria
  • Krems University Hospital
    Krems, 3500, Austria
  • Hospital Elisabethinen Linz
    Linz, Austria
  • LKH Salzburg University Hospital
    Salzburg, 5020, Austria
  • AKH - Medical University of Vienna
    Vienna, 1090, Austria
  • Clinic Floridsdorf
    Vienna, 1210, Austria
  • Klinikum Wels - Grieskirchen GmbH
    Wels, 4600, Austria
  • Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim
    Antwerp, 2020, Belgium
  • ULB Hopital Erasme
    Brussels, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UNIV UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • Serviços Medicos Respirar Sul Fluminense
    Barra Mansa, 27323240, Brazil
  • Hospital das Clinicas da Universidade Federal de Minas Gerais (HCUFMG)
    Belo Horizonte,Minas Gerais, 31270901, Brazil
  • Edumed - Educacao e Saude SA
    Curitiba, 80440-210, Brazil
  • CLARE - Clinica de Pneumologia
    Goiânia, 74110-030, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, 90035-074, Brazil
  • Instituto D´Or de Pesquisa e Ensino - Bahia
    Salvador, 41920-900, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    São Bernardo do Campo, 09780-000, Brazil
  • Hospital Alemao Oswaldo Cruz
    São Paulo, 01323-020, Brazil
  • University of Alberta Hospital (University of Alberta)
    Edmonton, Alberta T6G 2G3, Canada
  • Kelowna Respirology & Allergy Research
    Kelowna, British Columbia V1Y 3H5, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada

Showing the first 100 of 334 sites across 37 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER-ON). BMC Pulm Med. 2025 Dec 4;26(1):10. doi: 10.1186/s12890-025-03973-7. PubMed 41345848 ↗
  • Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; FIBRONEER-IPF Trial Investigators. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. PubMed 40387033 ↗
  • Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Gordat M, Liu Y, Stowasser S, Zoz DF, Wijsenbeek MS. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respir Res. 2023 Aug;10(1):e001563. doi: 10.1136/bmjresp-2022-001563. PubMed 37597969 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Aug 2024, 22 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 11, 2022
StartActual
Oct 6, 2022
Primary completionActual
Aug 16, 2024
CompletionActual
Dec 17, 2024
Results first posted
Sep 12, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05321069
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Oct 6, 2022
Primary completion
Aug 16, 2024
Completion
Dec 17, 2024
Results posted
Sep 12, 2025
Last update
Oct 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion